PUBLISHER: Allied Market Research | PRODUCT CODE: 1140295
PUBLISHER: Allied Market Research | PRODUCT CODE: 1140295
The global viral clearance market was valued at $425.93 million in 2021, and is projected to reach $977.84 million by 2031, registering a CAGR of 8.6% from 2022 to 2031.
Viral clearance is the removal of viral contamination using specialized membranes (mostly proteins) or chromatography. These protein solutions undergo viral clearance to inactivate or remove viral materials to ensure that therapeutic drugs derived from certain sources are fully rid of any viral contamination.
Viral clearance is a critical step in the manufacturing process that helps assure the safety of biologics such as biosimilars, antibodies, stem cell products, biopharmaceuticals, and others. Pharmaceutical and other product manufacturers need to be confirmed of its purification and manufacturing processes' capacity to inactivate or eliminate viruses or Transmissible spongiform encephalopathies(TSE) agents, as well as assure product safety.
The key factors that drive the growth of the market are rise in investments in the biotechnology and the pharmaceutical companies. There has been a rise in drug launches, increase in R&D investments, and rise in the possibility of cell culture contamination, recent advancements in nano-filtration technology, large economic burden and incidence of chronic diseases which is projected to provide huge opportunities for the growth of the viral clearance market. Along with this, rise in pharmaceutical outsourcing and increase in emerging markets are creating opportunities for the growth of the viral clearance market.
However, ever increasing cost and time-intensive drug development process are creating hurdles in the viral clearance market. In addition, increased degree of consolidation is also obstructing the growth of the market.
The viral clearance market is segmented on the basis of method, application, end user, and region. By method, it is categorized into viral removal, and viral inactivation. Viral removal is further divided into chromatography, nanofiltration, and precipitation. Viral inactivation is further categorized into low pH, solvent detergent method, heat pasteurization, and other viral inactivation methods. Depending on application, it is classified into recombinant proteins, blood and blood products, cellular and gene therapy products, vaccines, and other applications. By end user, it is categorized into pharmaceutical & biotechnology companies, contract research organizations, academic research institutes, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
North America accounted for the largest market share in the viral clearance market in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in demand for biopharmaceutical and upsurge in demand for advanced technologies in the purification of recombinant proteins produced by animal cell cultures to create high-value products of modern biotechnology.
The report provides a comprehensive analysis of the key players that operate in the global viral clearance market. The key companies profiled in the report include Allure Medical Group, Charles River Laboratories International, Inc., Clean Cells, Creative Biogene, Eurofins Scientific SE, Maravai Lifesciences Holding, Inc., Merck KGaA, Sartorius Stedium Biotech, Syngene International Limited, and Wuxi Biologics Inc.
Key Benefits For Stakeholders
Key Market Segments
By Method
By Application
By End User
By Region